AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3994010 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental, nitrous oxide and oxygen, enflurane, plus muscle relaxant
Number of subjects: 30
Study 3994010 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental, nitrous oxide and oxygen, narcotic, plus muscle relaxant
Number of subjects: 30
Study 3994010 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with tetracaine
Number of subjects: 30
Study 29966458 — intervention group
Group type: EXPERIMENTAL
Intervention: DNR 36 mg/m2
Number of subjects: 307
Study 29966458 — intervention group
Group type: COMPARATOR
Intervention: DOX 30 mg/m2
Number of subjects: 307
Study 28701292 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored text message intervention (SMS group)
Number of subjects: 1139
Study 28701292 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1139
Study 25246512 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Dopa
Number of subjects: 0
Study 25246512 — intervention group
Group type: EXPERIMENTAL
Intervention: Salient loss outcomes
Number of subjects: 0
Study 25246512 — intervention group
Group type: EXPERIMENTAL
Intervention: Null (neutral) reversal cues
Number of subjects: 0
Study 25246512 — intervention group
Group type: EXPERIMENTAL
Intervention: Salient reversal cues
Number of subjects: 0
Study 24410834 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy with pitavastatin
Number of subjects: 50
Study 24410834 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering therapy with pitavastatin
Number of subjects: 50
Study 24410834 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin use
Number of subjects: 50
Study 24410834 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
Number of subjects: 50
Study 24410834 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum DHA
Number of subjects: 50
Study 22913431 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational needs assessment tool and tailored educational interventions
Number of subjects: 5
Study 19414572 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg iclaprim/kg
Number of subjects: 59
Study 19414572 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 mg iclaprim/kg
Number of subjects: 59
Study 19414572 — intervention group
Group type: COMPARATOR
Intervention: 1 g vancomycin
Number of subjects: 59
Study 17456225 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass allergen tablet (GRAZAX)
Number of subjects: 17000000
Study 17456225 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment (antihistamines and topical steroids)
Number of subjects: 17000000
Study 15006124 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription by general practitioners for brisk exercise (30 minutes per day, 5 days per week)
Number of subjects: 151
Study 15006124 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling by practice nurses based on psychological theory
Number of subjects: 151
Study 15006124 — intervention group
Group type: COMPARATOR
Intervention: Use of the Health Education Authority booklet 'Getting active, feeling fit'
Number of subjects: 151
Study 15006124 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of prescription and counselling
Number of subjects: 151
Study 11605558 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantically similar encoding pairs (e.g., alluring-PRETTY)
Number of subjects: 0
Study 11605558 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantically contrasting encoding pairs (e.g., drab-PRETTY)
Number of subjects: 0
Study 11605558 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantically unrelated encoding pairs (e.g., sore-PRETTY)
Number of subjects: 0
Study 11605558 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantically similar generation pairs (e.g., beautiful-PRETTY)
Number of subjects: 0
Study 11605558 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantically contrasting generation pairs (e.g., ugly-PRETTY)
Number of subjects: 0
Study 9520826 — intervention group
Group type: EXPERIMENTAL
Intervention: Demeclocycline (1200 mg daily, starting 5 days preoperatively to postoperative day 2)
Number of subjects: 30
Study 9520826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8084686 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in sports (field hockey and athletics) for 10 weeks, 45 minutes daily
Number of subjects: 288
Study 8084686 — intervention group
Group type: COMPARATOR
Intervention: Control group (96 subjects)
Number of subjects: 288
Study 2573138 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic contrast medium
Number of subjects: 50
Study 2573138 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ionic contrast medium
Number of subjects: 50
Study 2573138 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 50
Study 30451582 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric plication (LGP)
Number of subjects: 91
Study 30451582 — intervention group
Group type: COMPARATOR
Intervention: Mini gastric bypass (MGB)
Number of subjects: 91
Study 28688677 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied with an InGaAlP diode (660nm‐100mW‐1J‐4J/cm2)
Number of subjects: 94
Study 28688677 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 94
Study 25720702 — intervention group
Group type: COMPARATOR
Intervention: Traditional round block technique (Group A)
Number of subjects: 44
Study 25720702 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified round block technique with cardinal glandulo-glandular sutures (Group B)
Number of subjects: 44
Study 23966556 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP(5)-IPV-Hib
Number of subjects: 0
Study 23966556 — intervention group
Group type: COMPARATOR
Intervention: DTaP(3)-IPV/Hib
Number of subjects: 0
Study 21516768 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloferon
Number of subjects: 0
Study 18805054 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 551
Study 18805054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 551
Study 16686906 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe and frequent headaches
Number of subjects: 56
Study 16686906 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine without aura
Number of subjects: 56
Study 16686906 — intervention group
Group type: EXPERIMENTAL
Intervention: TCD velocities
Number of subjects: 56
Study 16686906 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain MRI abnormalities
Number of subjects: 56
Study 15490785 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine iontophoresis (1 percent histamine dihydrochloride)
Number of subjects: 20
Study 15490785 — intervention group
Group type: COMPARATOR
Intervention: Direct Current (without histamine)
Number of subjects: 20
Study 11447507 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone
Number of subjects: 617
Study 11447507 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 617
Study 9429740 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct administration into the duodenum (40 mg)
Number of subjects: 4
Study 9429740 — intervention group
Group type: COMPARATOR
Intervention: Oral administration (40 mg)
Number of subjects: 4
Study 8510982 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% delmopinol HCl
Number of subjects: 6
Study 8510982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 15791755 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviewer controls
Number of subjects: 0
Study 15791755 — intervention group
Group type: COMPARATOR
Intervention: Past studies
Number of subjects: 0
Study 31371114 — intervention group
Group type: EXPERIMENTAL
Intervention: Armolipid Plus™ (AP)
Number of subjects: 158
Study 31371114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 30526512 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufficient fruits and vegetables consumption
Number of subjects: 426
Study 30526512 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufficient physical activity
Number of subjects: 426
Study 30526512 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco use
Number of subjects: 426
Study 30526512 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmful alcohol drinking
Number of subjects: 426
Study 30526512 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary level education
Number of subjects: 426
Study 30526512 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 20-34 years
Number of subjects: 426
Study 30526512 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest wealth index
Number of subjects: 426
Study 26330379 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine maintenance tocolysis
Number of subjects: 170
Study 26330379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 24794721 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous peginterferon beta‐1a 125 μg every 2 weeks
Number of subjects: 1516
Study 24794721 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous peginterferon beta‐1a 125 μg every 4 weeks
Number of subjects: 1516
Study 24794721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1516
Study 24794721 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon every 2 weeks
Number of subjects: 1516
Study 24794721 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon every 4 weeks
Number of subjects: 1516
Study 21777510 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) at 135 Hz (90-μs pulsewidth)
Number of subjects: 8
Study 20484128 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (aromatase inhibitor) to lower estradiol and increase testosterone (group T)
Number of subjects: 20
Study 20484128 — intervention group
Group type: COMPARATOR
Intervention: Letrozole plus E(2) patches to lower testosterone and raise estradiol (group E)
Number of subjects: 20
Study 18713923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 18713923 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-2 adrenergic blockade with yohimbine
Number of subjects: 56
Study 16477766 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (200 IU/day)
Number of subjects: 100
Study 16477766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 12027070 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg albuterol/HFA 134a
Number of subjects: 63
Study 12027070 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg albuterol/HFA 134a
Number of subjects: 63
Study 12027070 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg albuterol/HFA 134a
Number of subjects: 63
Study 12027070 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg albuterol/CFC
Number of subjects: 63
Study 12027070 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg albuterol/CFC
Number of subjects: 63
Study 12027070 — intervention group
Group type: COMPARATOR
Intervention: Placebo/HFA 134a
Number of subjects: 63
Study 11305737 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (2 ng/min/kg)
Number of subjects: 35
Study 11305737 — intervention group
Group type: COMPARATOR
Intervention: Alprostadil (4.4 ng/min/kg)
Number of subjects: 35
Study 8868276 — intervention group
Group type: EXPERIMENTAL
Intervention: Words condition
Number of subjects: 0
Study 8868276 — intervention group
Group type: COMPARATOR
Intervention: Pictures condition
Number of subjects: 0
Study 1947972 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine with 1:100,000 epinephrine (EPI)
Number of subjects: 74
Study 1947972 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine with 1:100,000 epinephrine (EPI)
Number of subjects: 74
Study 6682667 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox 70 (4 x 10 ml/die)
Number of subjects: 15
Study 6682667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31612909 — intervention group
Group type: EXPERIMENTAL
Intervention: atezo + nab‐P
Number of subjects: 65
Study 31612909 — intervention group
Group type: COMPARATOR
Intervention: plac + nab‐P
Number of subjects: 65
Study 31612909 — intervention group
Group type: EXPERIMENTAL
Intervention: atezo + nab‐P (PD-L1-positive subgroup)
Number of subjects: 65
Study 31612909 — intervention group
Group type: COMPARATOR
Intervention: plac + nab‐P (PD-L1-positive subgroup)
Number of subjects: 65
Study 28650192 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 161
Study 28650192 — intervention group
Group type: COMPARATOR
Intervention: Panic-Focused Psychodynamic Psychotherapy (PFPP)
Number of subjects: 161
Study 26011779 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil (150‐250 mg/day)
Number of subjects: 60
Study 26011779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23230975 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus <3 ng/mL
Number of subjects: 556
Study 23230975 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus ≥ 12 ng/mL
Number of subjects: 556
Study 23230975 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus 3-8 ng/mL and CsA <100 ng/mL
Number of subjects: 556
Study 23230975 — intervention group
Group type: EXPERIMENTAL
Intervention: very low or very high everolimus trough concentrations
Number of subjects: 556
Study 22105589 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of modafinil (3 doses, given 8 hourly)
Number of subjects: 80
Study 22105589 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of modafinil (3 doses, given 8 hourly)
Number of subjects: 80
Study 22105589 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of modafinil (2 doses) plus placebo (1 dose, given 8 hourly)
Number of subjects: 80
Study 22105589 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 doses, given 8 hourly)
Number of subjects: 80
Study 19761889 — intervention group
Group type: EXPERIMENTAL
Intervention: Mashed potato with 1% HV‐HPMC
Number of subjects: 15
Study 19761889 — intervention group
Group type: EXPERIMENTAL
Intervention: Mashed potato with 2% HV‐HPMC
Number of subjects: 15
Study 19761889 — intervention group
Group type: EXPERIMENTAL
Intervention: Mashed potato with 4% HV‐HPMC
Number of subjects: 15
Study 19761889 — intervention group
Group type: COMPARATOR
Intervention: Standard mashed potato
Number of subjects: 15
Study 19761889 — intervention group
Group type: EXPERIMENTAL
Intervention: Mashed potato with HV‐HPMC (all doses)
Number of subjects: 15
Study 19761889 — intervention group
Group type: EXPERIMENTAL
Intervention: HV‐HPMC doses
Number of subjects: 15
Study 16490891 — intervention group
Group type: EXPERIMENTAL
Intervention: molgramostim (3 microg/kg for 4 days)
Number of subjects: 58
Study 16490891 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 58
Study 11834140 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhetinic acid (GA) 500 mg
Number of subjects: 40
Study 11834140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10613410 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-fine whole-grain wheat flour (UFWF)
Number of subjects: 26
Study 10613410 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional whole-grain wheat flour (WWF)
Number of subjects: 26
Study 10613410 — intervention group
Group type: COMPARATOR
Intervention: White bread
Number of subjects: 26
Study 10613410 — intervention group
Group type: COMPARATOR
Intervention: Glucose solution
Number of subjects: 26
Study 7583255 — intervention group
Group type: EXPERIMENTAL
Intervention: Deviant stimuli presented alone
Number of subjects: 8
Study 7583255 — intervention group
Group type: COMPARATOR
Intervention: Deviant stimuli presented among standards
Number of subjects: 8
Study 2303961 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulators (experimental group)
Number of subjects: 44
Study 2303961 — intervention group
Group type: COMPARATOR
Intervention: Dummy stimulators (control group)
Number of subjects: 44
Study 434280 — intervention group
Group type: EXPERIMENTAL
Intervention: High status interviewers (identified physicians)
Number of subjects: 0
Study 434280 — intervention group
Group type: COMPARATOR
Intervention: Low status interviewers
Number of subjects: 0
Study 434280 — intervention group
Group type: COMPARATOR
Intervention: Lay interviewers
Number of subjects: 0
Study 6645593 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous removal of IAB (Group I)
Number of subjects: 38
Study 6645593 — intervention group
Group type: COMPARATOR
Intervention: Surgical removal of IAB (Group II)
Number of subjects: 38
Study 31356267 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine-based home management program (THMP)
Number of subjects: 106
Study 31356267 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 106
Study 29429541 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat (LF) diet
Number of subjects: 0
Study 29429541 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately high-protein (MHP) diet
Number of subjects: 0
Study 28300813 — intervention group
Group type: EXPERIMENTAL
Intervention: cytoflavin
Number of subjects: 74
Study 28300813 — intervention group
Group type: COMPARATOR
Intervention: comparison group (control)
Number of subjects: 74
Study 23804555 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological rehabilitation (computer‐based attention and working memory retraining, psychoeducation, strategy learning, psychological support)
Number of subjects: 102
Study 23804555 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 102
Study 22711171 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg/day)
Number of subjects: 84
Study 22711171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 20576419 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol 240 mg
Number of subjects: 7
Study 20576419 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol 480 mg
Number of subjects: 7
Study 20576419 — intervention group
Group type: COMPARATOR
Intervention: Cough control (no mannitol)
Number of subjects: 7
Study 17591126 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol administration with bispectral index monitoring (group B)
Number of subjects: 20
Study 17591126 — intervention group
Group type: COMPARATOR
Intervention: Routine anaesthesia with propofol at target concentration (group C)
Number of subjects: 20
Study 17591126 — intervention group
Group type: COMPARATOR
Intervention: Group C (control)
Number of subjects: 20
Study 17591126 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (intervention)
Number of subjects: 20
Study 16230244 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour clamping drainage (group 1)
Number of subjects: 89
Study 16230244 — intervention group
Group type: COMPARATOR
Intervention: Nonclamping drainage (group 2)
Number of subjects: 89
Study 12453546 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg oral morphine four times daily for 4 days (2.5 mg if creatinine > 200 micromol/l)
Number of subjects: 10
Study 12453546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10747212 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 54
Study 10747212 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone
Number of subjects: 54
Study 7793547 — intervention group
Group type: COMPARATOR
Intervention: 0.125% bupivacaine alone (control group)
Number of subjects: 120
Study 7793547 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil at 266 micrograms.h‐1
Number of subjects: 120
Study 7793547 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil at 400 micrograms.h‐1
Number of subjects: 120
Study 7793547 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamorphine at 400 micrograms.h‐1
Number of subjects: 120
Study 7793547 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamorphine at 533 micrograms.h‐1
Number of subjects: 120
Study 7793547 — intervention group
Group type: EXPERIMENTAL
Intervention: All opioid groups (alfentanil and diamorphine)
Number of subjects: 120
Study 7793547 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.125% bupivacaine alone)
Number of subjects: 120
Study 7793547 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamorphine at highest dose (533 micrograms.h‐1)
Number of subjects: 120
Study 7793547 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study 1822492 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical dinoprostone 0.5 mg gel (Group 1, n = 24)
Number of subjects: 100
Study 1822492 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical administration of PGE2 1.5 mg on Surgicel (Group 2, n = 26)
Number of subjects: 100
Study 1822492 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical dinoprostone 0.5 mg gel (Group 3, n = 28)
Number of subjects: 100
Study 1822492 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of PGE2 2.25 mg on a Spongel (Group 4, n = 22)
Number of subjects: 100
Study 7333752 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained subjects
Number of subjects: 29
Study 7333752 — intervention group
Group type: COMPARATOR
Intervention: Sedentary subjects
Number of subjects: 29
Study 31498469 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy (TTh) injections (>12 injections)
Number of subjects: 189491
Study 31498469 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy (TTh) topical gels (>330 days supply)
Number of subjects: 189491
Study 31498469 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy (injection and gel) in nondiabetics
Number of subjects: 189491
Study 31498469 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy injections in diabetics
Number of subjects: 189491
Study 29800370 — intervention group
Group type: EXPERIMENTAL
Intervention: Live-attenuated tetravalent dengue vaccine (TDV)
Number of subjects: 0
Study 27790333 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactocare® (Synbiotic containing 1 billion CFU/Capsule of various probiotics)
Number of subjects: 72
Study 27790333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72